Akhil Wadhera is a Dermatology physician affiliated with Kaiser Permanente. OpenAlex indexes 17 publications with 441 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20242 payments
- Galderma Laboratories, L.P.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
29.5%Azole Antifungal15.2%Ketoconazole100%Part D<11 patientsTetracycline-class Drug14.3%Doxycycline Monohydrate100%Part D≥13 patientsSensory organs
24.1%Corticosteroid24.1%Betamethasone Diprop Augmented56%Clobetasol Propionate44%Part D<11 patientsCancer & immunology
20.5%Phosphodiesterase 4 Inhibitor10.7%Otezla100%Part D<11 patientsCalcineurin inhibitor9.8%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Self-care versus assisted-care outcomes after laser-assisted marsupialization for hidradenitis suppurativa
Journal of the American Academy of Dermatology
2026 - Surgical Management of Hidradenitis Suppurativa Using Staged Carbon Dioxide Laser Marsupialization
Journal of Clinical Medicine
2026 - 76415 Treatment of Argyria using 785-nm and 730-nm Picosecond Lasers
Journal of the American Academy of Dermatology
2026 - 72543 Hidradenitis Suppurativa: Successful Management with Staged Carbon Dioxide Laser Marsupialization
Journal of the American Academy of Dermatology
2026 - 74650 Consensus Study on the Best Practices of Laser Hair Reduction for Hidradenitis Suppurativa
Journal of the American Academy of Dermatology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Louis Fehrenbacher, MD
Kaiser Permanente
Susy Peng, MD
Kaiser Permanente
Prasanth Manthena, MD
Kaiser Permanente
Alan Go, MD
Kaiser Permanente
Robert Modlin, MD
University of California, Los Angeles
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Joel Gelfand, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”